BACKGROUND: The accumulation of the misfolded forms of cellular prion protein, i.e. prions (PrPSc), in the brain is one of the crucial characteristics of fatal neurodegenerative disorders, called transmissible spongiform encephalopathies (TSEs). Cellular prion protein is normally linked to the cell surface by the glycosylphosphatidylinositol (GPI) anchor. There is accumulating evidence that the GPI-anchorless prion protein may act as an accelerator of formation and propagation of prions. In the TSE affected human brain we have previously discovered a novel GPI-anchorless prion protein fragment, named PrP226*, which ends with the tyrosine 226. This fragment can be labeled specifically by the monoclonal antibody V5B2. METHODS: We developed a DELFIA based assay for quick and sensitive detection of the PrP226* fragment in human brain tissue homogenates. By calculating the ratio between the signals of native (N) and denatured (D) samples applied to the assay we were able to observe significant difference between 24 TSE affected brains and 10 control brains. The presence of PrP226* in brain tissue was confirmed by western blot. RESULTS: Our results demonstrate that PrP226* is present in small quantities in healthy human brain, whereas in degenerated brain it accumulates in prion aggregates, proportionally to PrPSc. Samples with high D/N ratio generally comprised more proteinase K resistant PrP, while no correlation was found between the quantity of PrP226* and standard classification of Creutzfeldt-Jakob disease (CJD). CONCLUSIONS: In the present study we show that the PrP226* fragment accumulates in prion aggregates and after being released from them by a denaturation procedure, could serve as a proteinase K digestion independent biomarker for human TSEs. The PrP226* assay described in this paper offers a tool to follow and study this unique anchorless PrP fragment in various parts of human brain and possibly also in other tissues and body fluids.

Department of Pathology and Molecular Medicine Thomayer Hospital Prague Czech Republic

Institute of Immunology and Microbiology 1 st Faculty of Medicine Charles University Prague Czech Republic

Institute of Macromolecular Chemistry v i i Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc18034491

003      

CZ-PrNML

005      

20190104103706.0

007      

ta

008      

181009s2013 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1186/1471-2377-13-126 $2 doi

035    __

$a (PubMed)24063733

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Dvořáková, Eva $7 _AN046206 $u Institute of Immunology and Microbiology, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic

245    10

$a Detection of the GPI-anchorless prion protein fragment PrP226* in human brain / $c E Dvorakova, T Vranac, O Janouskova, M Cernilec, S Koren, A Lukan, J Novakova, R Matej, K Holada, Serbec V Curin

520    9_

$a BACKGROUND: The accumulation of the misfolded forms of cellular prion protein, i.e. prions (PrPSc), in the brain is one of the crucial characteristics of fatal neurodegenerative disorders, called transmissible spongiform encephalopathies (TSEs). Cellular prion protein is normally linked to the cell surface by the glycosylphosphatidylinositol (GPI) anchor. There is accumulating evidence that the GPI-anchorless prion protein may act as an accelerator of formation and propagation of prions. In the TSE affected human brain we have previously discovered a novel GPI-anchorless prion protein fragment, named PrP226*, which ends with the tyrosine 226. This fragment can be labeled specifically by the monoclonal antibody V5B2. METHODS: We developed a DELFIA based assay for quick and sensitive detection of the PrP226* fragment in human brain tissue homogenates. By calculating the ratio between the signals of native (N) and denatured (D) samples applied to the assay we were able to observe significant difference between 24 TSE affected brains and 10 control brains. The presence of PrP226* in brain tissue was confirmed by western blot. RESULTS: Our results demonstrate that PrP226* is present in small quantities in healthy human brain, whereas in degenerated brain it accumulates in prion aggregates, proportionally to PrPSc. Samples with high D/N ratio generally comprised more proteinase K resistant PrP, while no correlation was found between the quantity of PrP226* and standard classification of Creutzfeldt-Jakob disease (CJD). CONCLUSIONS: In the present study we show that the PrP226* fragment accumulates in prion aggregates and after being released from them by a denaturation procedure, could serve as a proteinase K digestion independent biomarker for human TSEs. The PrP226* assay described in this paper offers a tool to follow and study this unique anchorless PrP fragment in various parts of human brain and possibly also in other tissues and body fluids.

590    __

$a bohemika - dle Pubmed

650    02

$a proteiny 14-3-3 $x metabolismus $7 D048948

650    12

$a mozek $x metabolismus $x účinky léků $7 D001921

650    12

$a Creutzfeldtova-Jakobova nemoc $x patologie $7 D007562

650    02

$a endopeptidasa K $x farmakologie $7 D019286

650    02

$a ELISA $7 D004797

650    02

$a ženské pohlaví $7 D005260

650    02

$a glykosylfosfatidylinositoly $x metabolismus $7 D017261

650    02

$a lidé $7 D006801

650    02

$a mužské pohlaví $7 D008297

650    02

$a PrPSc proteiny $x metabolismus $x účinky léků $7 D018620

650    02

$a statistika jako téma $7 D013223

650    02

$a teplota $7 D013696

700    1_

$a Vranac T

700    1_

$a Janoušková, Olga $7 xx0100922 $u Institute of Immunology and Microbiology, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic; Institute of Macromolecular Chemistry v.i.i. Czech Republic

700    1_

$a Cernilec M

700    1_

$a Koren S

700    1_

$a Lukan A

700    1_

$a Nováková, Jana $u Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic

700    1_

$a Matěj, Radoslav, $d 1974- $7 xx0103860 $u Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic

700    1_

$a Holada, Karel $7 xx0061473 $u Institute of Immunology and Microbiology, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic

700    1_

$a Curin Serbec V

773    0_

$t BMC Neurology $g č. 13 (2013), s. 126 $p BMC Neurol $x 1471-2377 (elektronická verze) $w MED00008195

773    0_

$p BMC Neurol $g 13:126, 2013 Sep 25

910    __

$a ABA008 $y 4 $z 0

990    __

$a 20181009140615 $b ABA008

991    __

$a 20190104103901 $b ABA008

999    __

$a ok $b bmc $g 1340578 $s 1031488

BAS    __

$a 3

BMC    __

$a 2013 $c 13 $d 126 $x MED00008195 $i 1471-2377 (elektronická verze) $m BMC neurology

GRA    __

$a NT14145 $p MZ0

LZP    __

$a NLK 2018/lp